APO Research
Talk to an analyst

APO RESEARCH · REPORT

Semi-Solid Dosage Form

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Semi-Solid Dosage Form Market Analysis and Forecast 2026-2032

30 December 2025215 pages

Choose your research edition.

Industry ResearchSemi-Solid Dosage Form Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Semi-Solid Dosage Form Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Semi-Solid Dosage Form Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Semi-Solid Dosage Form Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Semi-Solid Dosage Form Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Semi-Solid Dosage Form market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Semi-Solid Dosage Form is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Semi-Solid Dosage Form is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Semi-Solid Dosage Form is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Semi-Solid Dosage Form is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Semi-Solid Dosage Form include Aclaris Therapeutics, Inc., Akorn Inc. (US), Allergan plc, Almirall, S.A, Bausch Health Companies, Biofrontera, Inc., Cipla Ltd, Crescita Therapeutics Inc. and Crown Laboratories Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Semi-Solid Dosage Form, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Semi-Solid Dosage Form, also provides the sales of main regions and countries. Of the upcoming market potential for Semi-Solid Dosage Form, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Semi-Solid Dosage Form sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Semi-Solid Dosage Form market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Semi-Solid Dosage Form sales, projected growth trends, production technology, application and end-user industry.

Semi-Solid Dosage Form Segment by Company

Aclaris Therapeutics, Inc.

Akorn Inc. (US)

Allergan plc

Almirall, S.A

Bausch Health Companies

Biofrontera, Inc.

Cipla Ltd

Crescita Therapeutics Inc.

Crown Laboratories Inc.

Encore Dermatology, Inc.

Glenmark Pharmaceuticals

Hisamitsu Pharmaceutical

Ingenus Pharmaceuticals

LEO Pharma

Mylan N.V.

Novartis AG

Perrigo Pharma

Taro Pharmaceutical Industries Ltd.

Teligent Pharma

Bayer AG

GlaxoSmithKline plc

Merck & Co

Johnson & Johnson

Nestlé SA

Sun Pharmaceuticals

Semi-Solid Dosage Form Segment by Type

Ointments

Gels

Others

Semi-Solid Dosage Form Segment by Application

Nasal Cavity

Skin

Vaginal Cavity

Rectal Cavity

Others

Semi-Solid Dosage Form Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Semi-Solid Dosage Form market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Semi-Solid Dosage Form and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Semi-Solid Dosage Form.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Semi-Solid Dosage Form in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Semi-Solid Dosage Form sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Semi-Solid Dosage Form Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ointments Major Manufacturers Table 3. Gels Major Manufacturers Table 4. Others Major Manufacturers Table 5. Global Semi-Solid Dosage Form Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Nasal Cavity Major Manufacturers Table 7. Skin Major Manufacturers Table 8. Vaginal Cavity Major Manufacturers Table 9. Rectal Cavity Major Manufacturers Table 10. Others Major Manufacturers Table 11. Semi-Solid Dosage Form Industry Trends Table 12. Semi-Solid Dosage Form Industry Drivers Table 13. Semi-Solid Dosage Form Industry Opportunities and Challenges Table 14. Semi-Solid Dosage Form Industry Restraints Table 15. Global Semi-Solid Dosage Form Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 16. Global Semi-Solid Dosage Form Revenue by Region (2021-2026) & (US$ Million) Table 17. Global Semi-Solid Dosage Form Revenue by Region (2027-2032) & (US$ Million) Table 18. Global Semi-Solid Dosage Form Revenue Market Share by Region (2021-2026) Table 19. Global Semi-Solid Dosage Form Revenue Market Share by Region (2027-2032) Table 20. Global Semi-Solid Dosage Form Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 21. Global Semi-Solid Dosage Form Sales by Region (2021-2026) & (K Units) Table 22. Global Semi-Solid Dosage Form Sales by Region (2027-2032) & (K Units) Table 23. Global Semi-Solid Dosage Form Sales Market Share by Region (2021-2026) Table 24. Global Semi-Solid Dosage Form Sales Market Share by Region (2027-2032) Table 25. Global Semi-Solid Dosage Form Revenue by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Semi-Solid Dosage Form Revenue Market Share by Manufacturers (2021-2026) Table 27. Global Semi-Solid Dosage Form Sales by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Semi-Solid Dosage Form Sales Market Share by Manufacturers (2021-2026) Table 29. Global Semi-Solid Dosage Form Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 30. Global Semi-Solid Dosage Form Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 31. Global Semi-Solid Dosage Form Key Manufacturers Manufacturing Sites & Headquarters Table 32. Global Semi-Solid Dosage Form Manufacturers, Product Type & Application Table 33. Global Semi-Solid Dosage Form Manufacturers' Establishment Date Table 34. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 35. Global Semi-Solid Dosage Form by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 36. Global Semi-Solid Dosage Form Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Semi-Solid Dosage Form Revenue by Type (2021-2026) & (US$ Million) Table 38. Global Semi-Solid Dosage Form Revenue by Type (2027-2032) & (US$ Million) Table 39. Global Semi-Solid Dosage Form Revenue Market Share by Type (2021-2026) Table 40. Global Semi-Solid Dosage Form Revenue Market Share by Type (2027-2032) Table 41. Global Semi-Solid Dosage Form Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 42. Global Semi-Solid Dosage Form Sales by Type (2021-2026) & (K Units) Table 43. Global Semi-Solid Dosage Form Sales by Type (2027-2032) & (K Units) Table 44. Global Semi-Solid Dosage Form Sales Market Share by Type (2021-2026) Table 45. Global Semi-Solid Dosage Form Sales Market Share by Type (2027-2032) Table 46. Global Semi-Solid Dosage Form Price by Type (2021-2026) & (US$/Unit) Table 47. Global Semi-Solid Dosage Form Price by Type (2027-2032) & (US$/Unit) Table 48. Global Semi-Solid Dosage Form Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Semi-Solid Dosage Form Revenue by Application (2021-2026) & (US$ Million) Table 50. Global Semi-Solid Dosage Form Revenue by Application (2027-2032) & (US$ Million) Table 51. Global Semi-Solid Dosage Form Revenue Market Share by Application (2021-2026) Table 52. Global Semi-Solid Dosage Form Revenue Market Share by Application (2027-2032) Table 53. Global Semi-Solid Dosage Form Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 54. Global Semi-Solid Dosage Form Sales by Application (2021-2026) & (K Units) Table 55. Global Semi-Solid Dosage Form Sales by Application (2027-2032) & (K Units) Table 56. Global Semi-Solid Dosage Form Sales Market Share by Application (2021-2026) Table 57. Global Semi-Solid Dosage Form Sales Market Share by Application (2027-2032) Table 58. Global Semi-Solid Dosage Form Price by Application (2021-2026) & (US$/Unit) Table 59. Global Semi-Solid Dosage Form Price by Application (2027-2032) & (US$/Unit) Table 60. Aclaris Therapeutics, Inc. Company Information Table 61. Aclaris Therapeutics, Inc. Business Overview Table 62. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 63. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio Table 64. Aclaris Therapeutics, Inc. Recent Development Table 65. Akorn Inc. (US) Company Information Table 66. Akorn Inc. (US) Business Overview Table 67. Akorn Inc. (US) Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio Table 69. Akorn Inc. (US) Recent Development Table 70. Allergan plc Company Information Table 71. Allergan plc Business Overview Table 72. Allergan plc Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Allergan plc Semi-Solid Dosage Form Product Portfolio Table 74. Allergan plc Recent Development Table 75. Almirall, S.A Company Information Table 76. Almirall, S.A Business Overview Table 77. Almirall, S.A Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Almirall, S.A Semi-Solid Dosage Form Product Portfolio Table 79. Almirall, S.A Recent Development Table 80. Bausch Health Companies Company Information Table 81. Bausch Health Companies Business Overview Table 82. Bausch Health Companies Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Bausch Health Companies Semi-Solid Dosage Form Product Portfolio Table 84. Bausch Health Companies Recent Development Table 85. Biofrontera, Inc. Company Information Table 86. Biofrontera, Inc. Business Overview Table 87. Biofrontera, Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio Table 89. Biofrontera, Inc. Recent Development Table 90. Cipla Ltd Company Information Table 91. Cipla Ltd Business Overview Table 92. Cipla Ltd Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Cipla Ltd Semi-Solid Dosage Form Product Portfolio Table 94. Cipla Ltd Recent Development Table 95. Crescita Therapeutics Inc. Company Information Table 96. Crescita Therapeutics Inc. Business Overview Table 97. Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio Table 99. Crescita Therapeutics Inc. Recent Development Table 100. Crown Laboratories Inc. Company Information Table 101. Crown Laboratories Inc. Business Overview Table 102. Crown Laboratories Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio Table 104. Crown Laboratories Inc. Recent Development Table 105. Encore Dermatology, Inc. Company Information Table 106. Encore Dermatology, Inc. Business Overview Table 107. Encore Dermatology, Inc. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio Table 109. Encore Dermatology, Inc. Recent Development Table 110. Glenmark Pharmaceuticals Company Information Table 111. Glenmark Pharmaceuticals Business Overview Table 112. Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 114. Glenmark Pharmaceuticals Recent Development Table 115. Hisamitsu Pharmaceutical Company Information Table 116. Hisamitsu Pharmaceutical Business Overview Table 117. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio Table 119. Hisamitsu Pharmaceutical Recent Development Table 120. Ingenus Pharmaceuticals Company Information Table 121. Ingenus Pharmaceuticals Business Overview Table 122. Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 124. Ingenus Pharmaceuticals Recent Development Table 125. LEO Pharma Company Information Table 126. LEO Pharma Business Overview Table 127. LEO Pharma Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. LEO Pharma Semi-Solid Dosage Form Product Portfolio Table 129. LEO Pharma Recent Development Table 130. Mylan N.V. Company Information Table 131. Mylan N.V. Business Overview Table 132. Mylan N.V. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Mylan N.V. Semi-Solid Dosage Form Product Portfolio Table 134. Mylan N.V. Recent Development Table 135. Novartis AG Company Information Table 136. Novartis AG Business Overview Table 137. Novartis AG Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Novartis AG Semi-Solid Dosage Form Product Portfolio Table 139. Novartis AG Recent Development Table 140. Perrigo Pharma Company Information Table 141. Perrigo Pharma Business Overview Table 142. Perrigo Pharma Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Perrigo Pharma Semi-Solid Dosage Form Product Portfolio Table 144. Perrigo Pharma Recent Development Table 145. Taro Pharmaceutical Industries Ltd. Company Information Table 146. Taro Pharmaceutical Industries Ltd. Business Overview Table 147. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio Table 149. Taro Pharmaceutical Industries Ltd. Recent Development Table 150. Teligent Pharma Company Information Table 151. Teligent Pharma Business Overview Table 152. Teligent Pharma Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Teligent Pharma Semi-Solid Dosage Form Product Portfolio Table 154. Teligent Pharma Recent Development Table 155. Bayer AG Company Information Table 156. Bayer AG Business Overview Table 157. Bayer AG Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Bayer AG Semi-Solid Dosage Form Product Portfolio Table 159. Bayer AG Recent Development Table 160. GlaxoSmithKline plc Company Information Table 161. GlaxoSmithKline plc Business Overview Table 162. GlaxoSmithKline plc Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio Table 164. GlaxoSmithKline plc Recent Development Table 165. Merck & Co Company Information Table 166. Merck & Co Business Overview Table 167. Merck & Co Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Merck & Co Semi-Solid Dosage Form Product Portfolio Table 169. Merck & Co Recent Development Table 170. Johnson & Johnson Company Information Table 171. Johnson & Johnson Business Overview Table 172. Johnson & Johnson Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. Johnson & Johnson Semi-Solid Dosage Form Product Portfolio Table 174. Johnson & Johnson Recent Development Table 175. Nestlé SA Company Information Table 176. Nestlé SA Business Overview Table 177. Nestlé SA Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 178. Nestlé SA Semi-Solid Dosage Form Product Portfolio Table 179. Nestlé SA Recent Development Table 180. Sun Pharmaceuticals Company Information Table 181. Sun Pharmaceuticals Business Overview Table 182. Sun Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 183. Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 184. Sun Pharmaceuticals Recent Development Table 185. North America Semi-Solid Dosage Form Revenue by Type (2021-2026) & (US$ Million) Table 186. North America Semi-Solid Dosage Form Revenue by Type (2027-2032) & (US$ Million) Table 187. North America Semi-Solid Dosage Form Sales by Type (2021-2026) & (K Units) Table 188. North America Semi-Solid Dosage Form Sales by Type (2027-2032) & (K Units) Table 189. North America Semi-Solid Dosage Form Sales Price by Type (2021-2026) & (US$/Unit) Table 190. North America Semi-Solid Dosage Form Sales Price by Type (2027-2032) & (US$/Unit) Table 191. North America Semi-Solid Dosage Form Revenue by Application (2021-2026) & (US$ Million) Table 192. North America Semi-Solid Dosage Form Revenue by Application (2027-2032) & (US$ Million) Table 193. North America Semi-Solid Dosage Form Sales by Application (2021-2026) & (K Units) Table 194. North America Semi-Solid Dosage Form Sales by Application (2027-2032) & (K Units) Table 195. North America Semi-Solid Dosage Form Sales Price by Application (2021-2026) & (US$/Unit) Table 196. North America Semi-Solid Dosage Form Sales Price by Application (2027-2032) & (US$/Unit) Table 197. North America Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 198. North America Semi-Solid Dosage Form Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 199. North America Semi-Solid Dosage Form Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 200. North America Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 201. North America Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 202. North America Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 203. North America Semi-Solid Dosage Form Sales Price by Country (2021-2026) & (US$/Unit) Table 204. North America Semi-Solid Dosage Form Sales Price by Country (2027-2032) & (US$/Unit) Table 205. United States Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 206. Canada Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 207. Europe Semi-Solid Dosage Form Revenue by Type (2021-2026) & (US$ Million) Table 208. Europe Semi-Solid Dosage Form Revenue by Type (2027-2032) & (US$ Million) Table 209. Europe Semi-Solid Dosage Form Sales by Type (2021-2026) & (K Units) Table 210. Europe Semi-Solid Dosage Form Sales by Type (2027-2032) & (K Units) Table 211. Europe Semi-Solid Dosage Form Sales Price by Type (2021-2026) & (US$/Unit) Table 212. Europe Semi-Solid Dosage Form Sales Price by Type (2027-2032) & (US$/Unit) Table 213. Europe Semi-Solid Dosage Form Revenue by Application (2021-2026) & (US$ Million) Table 214. Europe Semi-Solid Dosage Form Revenue by Application (2027-2032) & (US$ Million) Table 215. Europe Semi-Solid Dosage Form Sales by Application (2021-2026) & (K Units) Table 216. Europe Semi-Solid Dosage Form Sales by Application (2027-2032) & (K Units) Table 217. Europe Semi-Solid Dosage Form Sales Price by Application (2021-2026) & (US$/Unit) Table 218. Europe Semi-Solid Dosage Form Sales Price by Application (2027-2032) & (US$/Unit) Table 219. Europe Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 220. Europe Semi-Solid Dosage Form Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 221. Europe Semi-Solid Dosage Form Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 222. Europe Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 223. Europe Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 224. Europe Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 225. Europe Semi-Solid Dosage Form Sales Price by Country (2021-2026) & (US$/Unit) Table 226. Europe Semi-Solid Dosage Form Sales Price by Country (2027-2032) & (US$/Unit) Table 227. Germany Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 228. France Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 229. U.K. Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 230. Italy Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 231. Netherlands Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 232. China Semi-Solid Dosage Form Revenue by Type (2021-2026) & (US$ Million) Table 233. China Semi-Solid Dosage Form Revenue by Type (2027-2032) & (US$ Million) Table 234. China Semi-Solid Dosage Form Sales by Type (2021-2026) & (K Units) Table 235. China Semi-Solid Dosage Form Sales by Type (2027-2032) & (K Units) Table 236. China Semi-Solid Dosage Form Sales Price by Type (2021-2026) & (US$/Unit) Table 237. China Semi-Solid Dosage Form Sales Price by Type (2027-2032) & (US$/Unit) Table 238. China Semi-Solid Dosage Form Revenue by Application (2021-2026) & (US$ Million) Table 239. China Semi-Solid Dosage Form Revenue by Application (2027-2032) & (US$ Million) Table 240. China Semi-Solid Dosage Form Sales by Application (2021-2026) & (K Units) Table 241. China Semi-Solid Dosage Form Sales by Application (2027-2032) & (K Units) Table 242. China Semi-Solid Dosage Form Sales Price by Application (2021-2026) & (US$/Unit) Table 243. China Semi-Solid Dosage Form Sales Price by Application (2027-2032) & (US$/Unit) Table 244. Asia Semi-Solid Dosage Form Revenue by Type (2021-2026) & (US$ Million) Table 245. Asia Semi-Solid Dosage Form Revenue by Type (2027-2032) & (US$ Million) Table 246. Asia Semi-Solid Dosage Form Sales by Type (2021-2026) & (K Units) Table 247. Asia Semi-Solid Dosage Form Sales by Type (2027-2032) & (K Units) Table 248. Asia Semi-Solid Dosage Form Sales Price by Type (2021-2026) & (US$/Unit) Table 249. Asia Semi-Solid Dosage Form Sales Price by Type (2027-2032) & (US$/Unit) Table 250. Asia Semi-Solid Dosage Form Revenue by Application (2021-2026) & (US$ Million) Table 251. Asia Semi-Solid Dosage Form Revenue by Application (2027-2032) & (US$ Million) Table 252. Asia Semi-Solid Dosage Form Sales by Application (2021-2026) & (K Units) Table 253. Asia Semi-Solid Dosage Form Sales by Application (2027-2032) & (K Units) Table 254. Asia Semi-Solid Dosage Form Sales Price by Application (2021-2026) & (US$/Unit) Table 255. Asia Semi-Solid Dosage Form Sales Price by Application (2027-2032) & (US$/Unit) Table 256. Asia Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 257. Asia Semi-Solid Dosage Form Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 258. Asia Semi-Solid Dosage Form Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 259. Asia Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 260. Asia Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 261. Asia Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 262. Asia Semi-Solid Dosage Form Sales Price by Country (2021-2026) & (US$/Unit) Table 263. Asia Semi-Solid Dosage Form Sales Price by Country (2027-2032) & (US$/Unit) Table 264. Japan Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 265. South Korea Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 266. India Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 267. Australia Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 268. China Taiwan Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 269. Southeast Asia Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 270. SAMEA Semi-Solid Dosage Form Revenue by Type (2021-2026) & (US$ Million) Table 271. SAMEA Semi-Solid Dosage Form Revenue by Type (2027-2032) & (US$ Million) Table 272. SAMEA Semi-Solid Dosage Form Sales by Type (2021-2026) & (K Units) Table 273. SAMEA Semi-Solid Dosage Form Sales by Type (2027-2032) & (K Units) Table 274. SAMEA Semi-Solid Dosage Form Sales Price by Type (2021-2026) & (US$/Unit) Table 275. SAMEA Semi-Solid Dosage Form Sales Price by Type (2027-2032) & (US$/Unit) Table 276. SAMEA Semi-Solid Dosage Form Revenue by Application (2021-2026) & (US$ Million) Table 277. SAMEA Semi-Solid Dosage Form Revenue by Application (2027-2032) & (US$ Million) Table 278. SAMEA Semi-Solid Dosage Form Sales by Application (2021-2026) & (K Units) Table 279. SAMEA Semi-Solid Dosage Form Sales by Application (2027-2032) & (K Units) Table 280. SAMEA Semi-Solid Dosage Form Sales Price by Application (2021-2026) & (US$/Unit) Table 281. SAMEA Semi-Solid Dosage Form Sales Price by Application (2027-2032) & (US$/Unit) Table 282. SAMEA Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 283. SAMEA Semi-Solid Dosage Form Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 284. SAMEA Semi-Solid Dosage Form Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 285. SAMEA Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 286. SAMEA Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 287. SAMEA Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 288. SAMEA Semi-Solid Dosage Form Sales Price by Country (2021-2026) & (US$/Unit) Table 289. SAMEA Semi-Solid Dosage Form Sales Price by Country (2027-2032) & (US$/Unit) Table 290. Brazil Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 291. Argentina Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 292. Chile Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 293. Colombia Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 294. Peru Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 295. Saudi Arabia Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 296. Israel Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 297. UAE Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 298. Turkey Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 299. Iran Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 300. Egypt Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Table 301. Key Raw Materials Table 302. Raw Materials Key Suppliers Table 303. Semi-Solid Dosage Form Distributors List Table 304. Semi-Solid Dosage Form Customers List Table 305. Research Programs/Design for This Report Table 306. Authors List of This Report Table 307. Secondary Sources Table 308. Primary Sources List of Figures Figure 1. Semi-Solid Dosage Form Image Figure 2. Global Semi-Solid Dosage Form Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Semi-Solid Dosage Form Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ointments Image Figure 5. Gels Image Figure 6. Others Image Figure 7. Global Semi-Solid Dosage Form Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Semi-Solid Dosage Form Market Size Share 2021 VS 2025 VS 2032 Figure 9. Nasal Cavity Image Figure 10. Skin Image Figure 11. Vaginal Cavity Image Figure 12. Rectal Cavity Image Figure 13. Others Image Figure 14. Global Semi-Solid Dosage Form Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Semi-Solid Dosage Form Revenue (2021-2032) & (US$ Million) Figure 16. Global Semi-Solid Dosage Form Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 17. Global Semi-Solid Dosage Form Revenue Market Share by Region: 2025 Versus 2032 Figure 18. Global Semi-Solid Dosage Form Revenue Market Share by Region (2021-2032) Figure 19. Global Semi-Solid Dosage Form Sales (2021-2032) & (K Units) Figure 20. Global Semi-Solid Dosage Form Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 21. Global Semi-Solid Dosage Form Sales Market Share by Region (2021-2032) Figure 22. US & Canada & Mexico Semi-Solid Dosage Form Sales YoY (2021-2032) & (K Units) Figure 23. Europe Semi-Solid Dosage Form Sales YoY (2021-2032) & (K Units) Figure 24. China Semi-Solid Dosage Form Sales YoY (2021-2032) & (K Units) Figure 25. Asia (Excluding China) Semi-Solid Dosage Form Sales YoY (2021-2032) & (K Units) Figure 26. South America, Middle East and Africa Semi-Solid Dosage Form Sales YoY (2021-2032) & (K Units) Figure 27. Global Semi-Solid Dosage Form Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 28. Global Semi-Solid Dosage Form Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 29. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 30. Global Semi-Solid Dosage Form Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global Semi-Solid Dosage Form Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Semi-Solid Dosage Form Revenue Market Share by Type (2021-2032) Figure 33. Global Semi-Solid Dosage Form Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 34. Global Semi-Solid Dosage Form Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Semi-Solid Dosage Form Sales Market Share by Type (2021-2032) Figure 36. Global Semi-Solid Dosage Form Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 37. Global Semi-Solid Dosage Form Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Semi-Solid Dosage Form Revenue Market Share by Application (2021-2032) Figure 39. Global Semi-Solid Dosage Form Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 40. Global Semi-Solid Dosage Form Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Semi-Solid Dosage Form Sales Market Share by Application (2021-2032) Figure 42. North America Semi-Solid Dosage Form Revenue Share by Type (2021-2032) Figure 43. North America Semi-Solid Dosage Form Sales Share by Type (2021-2032) Figure 44. North America Semi-Solid Dosage Form Revenue Share by Application (2021-2032) Figure 45. North America Semi-Solid Dosage Form Sales Share by Application (2021-2032) Figure 46. North America Semi-Solid Dosage Form Revenue Share by Country (2021-2032) Figure 47. North America Semi-Solid Dosage Form Sales Share by Country (2021-2032) Figure 48. Europe Semi-Solid Dosage Form Revenue Share by Type (2021-2032) Figure 49. Europe Semi-Solid Dosage Form Sales Share by Type (2021-2032) Figure 50. Europe Semi-Solid Dosage Form Revenue Share by Application (2021-2032) Figure 51. Europe Semi-Solid Dosage Form Sales Share by Application (2021-2032) Figure 52. Europe Semi-Solid Dosage Form Revenue Share by Country (2021-2032) Figure 53. Europe Semi-Solid Dosage Form Sales Share by Country (2021-2032) Figure 54. China Semi-Solid Dosage Form Revenue Share by Type (2021-2032) Figure 55. China Semi-Solid Dosage Form Sales Share by Type (2021-2032) Figure 56. China Semi-Solid Dosage Form Revenue Share by Application (2021-2032) Figure 57. China Semi-Solid Dosage Form Sales Share by Application (2021-2032) Figure 58. Asia Semi-Solid Dosage Form Revenue Share by Type (2021-2032) Figure 59. Asia Semi-Solid Dosage Form Sales Share by Type (2021-2032) Figure 60. Asia Semi-Solid Dosage Form Revenue Share by Application (2021-2032) Figure 61. Asia Semi-Solid Dosage Form Sales Share by Application (2021-2032) Figure 62. Asia Semi-Solid Dosage Form Revenue Share by Country (2021-2032) Figure 63. Asia Semi-Solid Dosage Form Sales Share by Country (2021-2032) Figure 64. SAMEA Semi-Solid Dosage Form Revenue Share by Type (2021-2032) Figure 65. SAMEA Semi-Solid Dosage Form Sales Share by Type (2021-2032) Figure 66. SAMEA Semi-Solid Dosage Form Revenue Share by Application (2021-2032) Figure 67. SAMEA Semi-Solid Dosage Form Sales Share by Application (2021-2032) Figure 68. SAMEA Semi-Solid Dosage Form Revenue Share by Country (2021-2032) Figure 69. SAMEA Semi-Solid Dosage Form Sales Share by Country (2021-2032) Figure 70. Semi-Solid Dosage Form Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Semi-Solid Dosage Form Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Ointments
  • Gels
  • Others
Applications
  • Nasal Cavity
  • Skin
  • Vaginal Cavity
  • Rectal Cavity
  • Others
Companies covered
  • Aclaris Therapeutics, Inc.
  • Akorn Inc. (US)
  • Allergan plc
  • Almirall, S.A
  • Bausch Health Companies
  • Biofrontera, Inc.
  • Cipla Ltd
  • Crescita Therapeutics Inc.
  • Crown Laboratories Inc.
  • Encore Dermatology, Inc.
  • Glenmark Pharmaceuticals
  • Hisamitsu Pharmaceutical
  • Ingenus Pharmaceuticals
  • LEO Pharma
  • Mylan N.V.
  • Novartis AG
  • Perrigo Pharma
  • Taro Pharmaceutical Industries Ltd.
  • Teligent Pharma
  • Bayer AG
  • GlaxoSmithKline plc
  • Merck & Co
  • Johnson & Johnson
  • Nestlé SA
  • Sun Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Semi-Solid Dosage Form Market by Type
  3. 1.2.1 Global Semi-Solid Dosage Form Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ointments
  5. 1.2.3 Gels
  6. 1.2.4 Others
  7. 1.3 Semi-Solid Dosage Form Market by Application
  8. 1.3.1 Global Semi-Solid Dosage Form Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Nasal Cavity
  10. 1.3.3 Skin
  11. 1.3.4 Vaginal Cavity
  12. 1.3.5 Rectal Cavity
  13. 1.3.6 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Semi-Solid Dosage Form Market Dynamics
  1. 2.1 Semi-Solid Dosage Form Industry Trends
  2. 2.2 Semi-Solid Dosage Form Industry Drivers
  3. 2.3 Semi-Solid Dosage Form Industry Opportunities and Challenges
  4. 2.4 Semi-Solid Dosage Form Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Semi-Solid Dosage Form Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Semi-Solid Dosage Form Revenue by Region
  3. 3.2.1 Global Semi-Solid Dosage Form Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Semi-Solid Dosage Form Revenue by Region (2021-2026)
  5. 3.2.3 Global Semi-Solid Dosage Form Revenue by Region (2027-2032)
  6. 3.2.4 Global Semi-Solid Dosage Form Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Semi-Solid Dosage Form Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Semi-Solid Dosage Form Sales by Region
  9. 3.4.1 Global Semi-Solid Dosage Form Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Semi-Solid Dosage Form Sales by Region (2021-2026)
  11. 3.4.3 Global Semi-Solid Dosage Form Sales by Region (2027-2032)
  12. 3.4.4 Global Semi-Solid Dosage Form Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Semi-Solid Dosage Form Revenue by Manufacturers
  2. 4.1.1 Global Semi-Solid Dosage Form Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Semi-Solid Dosage Form Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Semi-Solid Dosage Form Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Semi-Solid Dosage Form Sales by Manufacturers
  6. 4.2.1 Global Semi-Solid Dosage Form Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Semi-Solid Dosage Form Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Semi-Solid Dosage Form Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Semi-Solid Dosage Form Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Semi-Solid Dosage Form Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Semi-Solid Dosage Form Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Semi-Solid Dosage Form Manufacturers, Product Type & Application
  13. 4.7 Global Semi-Solid Dosage Form Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Semi-Solid Dosage Form Market CR5 and HHI
  16. 4.8.2 2025 Semi-Solid Dosage Form Tier 1, Tier 2, and Tier 3
5 Semi-Solid Dosage Form Market by Type
  1. 5.1 Global Semi-Solid Dosage Form Revenue by Type
  2. 5.1.1 Global Semi-Solid Dosage Form Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Semi-Solid Dosage Form Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Semi-Solid Dosage Form Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Semi-Solid Dosage Form Sales by Type
  6. 5.2.1 Global Semi-Solid Dosage Form Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Semi-Solid Dosage Form Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Semi-Solid Dosage Form Sales Market Share by Type (2021-2032)
  9. 5.3 Global Semi-Solid Dosage Form Price by Type
6 Semi-Solid Dosage Form Market by Application
  1. 6.1 Global Semi-Solid Dosage Form Revenue by Application
  2. 6.1.1 Global Semi-Solid Dosage Form Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Semi-Solid Dosage Form Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Semi-Solid Dosage Form Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Semi-Solid Dosage Form Sales by Application
  6. 6.2.1 Global Semi-Solid Dosage Form Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Semi-Solid Dosage Form Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Semi-Solid Dosage Form Sales Market Share by Application (2021-2032)
  9. 6.3 Global Semi-Solid Dosage Form Price by Application
7 Company Profiles
  1. 7.1 Aclaris Therapeutics, Inc.
  2. 7.1.1 Aclaris Therapeutics, Inc. Company Information
  3. 7.1.2 Aclaris Therapeutics, Inc. Business Overview
  4. 7.1.3 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio
  6. 7.1.5 Aclaris Therapeutics, Inc. Recent Developments
  7. 7.2 Akorn Inc. (US)
  8. 7.2.1 Akorn Inc. (US) Company Information
  9. 7.2.2 Akorn Inc. (US) Business Overview
  10. 7.2.3 Akorn Inc. (US) Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio
  12. 7.2.5 Akorn Inc. (US) Recent Developments
  13. 7.3 Allergan plc
  14. 7.3.1 Allergan plc Company Information
  15. 7.3.2 Allergan plc Business Overview
  16. 7.3.3 Allergan plc Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Allergan plc Semi-Solid Dosage Form Product Portfolio
  18. 7.3.5 Allergan plc Recent Developments
  19. 7.4 Almirall, S.A
  20. 7.4.1 Almirall, S.A Company Information
  21. 7.4.2 Almirall, S.A Business Overview
  22. 7.4.3 Almirall, S.A Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Almirall, S.A Semi-Solid Dosage Form Product Portfolio
  24. 7.4.5 Almirall, S.A Recent Developments
  25. 7.5 Bausch Health Companies
  26. 7.5.1 Bausch Health Companies Company Information
  27. 7.5.2 Bausch Health Companies Business Overview
  28. 7.5.3 Bausch Health Companies Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bausch Health Companies Semi-Solid Dosage Form Product Portfolio
  30. 7.5.5 Bausch Health Companies Recent Developments
  31. 7.6 Biofrontera, Inc.
  32. 7.6.1 Biofrontera, Inc. Company Information
  33. 7.6.2 Biofrontera, Inc. Business Overview
  34. 7.6.3 Biofrontera, Inc. Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio
  36. 7.6.5 Biofrontera, Inc. Recent Developments
  37. 7.7 Cipla Ltd
  38. 7.7.1 Cipla Ltd Company Information
  39. 7.7.2 Cipla Ltd Business Overview
  40. 7.7.3 Cipla Ltd Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Cipla Ltd Semi-Solid Dosage Form Product Portfolio
  42. 7.7.5 Cipla Ltd Recent Developments
  43. 7.8 Crescita Therapeutics Inc.
  44. 7.8.1 Crescita Therapeutics Inc. Company Information
  45. 7.8.2 Crescita Therapeutics Inc. Business Overview
  46. 7.8.3 Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio
  48. 7.8.5 Crescita Therapeutics Inc. Recent Developments
  49. 7.9 Crown Laboratories Inc.
  50. 7.9.1 Crown Laboratories Inc. Company Information
  51. 7.9.2 Crown Laboratories Inc. Business Overview
  52. 7.9.3 Crown Laboratories Inc. Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio
  54. 7.9.5 Crown Laboratories Inc. Recent Developments
  55. 7.10 Encore Dermatology, Inc.
  56. 7.10.1 Encore Dermatology, Inc. Company Information
  57. 7.10.2 Encore Dermatology, Inc. Business Overview
  58. 7.10.3 Encore Dermatology, Inc. Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio
  60. 7.10.5 Encore Dermatology, Inc. Recent Developments
  61. 7.11 Glenmark Pharmaceuticals
  62. 7.11.1 Glenmark Pharmaceuticals Company Information
  63. 7.11.2 Glenmark Pharmaceuticals Business Overview
  64. 7.11.3 Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  66. 7.11.5 Glenmark Pharmaceuticals Recent Developments
  67. 7.12 Hisamitsu Pharmaceutical
  68. 7.12.1 Hisamitsu Pharmaceutical Company Information
  69. 7.12.2 Hisamitsu Pharmaceutical Business Overview
  70. 7.12.3 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio
  72. 7.12.5 Hisamitsu Pharmaceutical Recent Developments
  73. 7.13 Ingenus Pharmaceuticals
  74. 7.13.1 Ingenus Pharmaceuticals Company Information
  75. 7.13.2 Ingenus Pharmaceuticals Business Overview
  76. 7.13.3 Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  78. 7.13.5 Ingenus Pharmaceuticals Recent Developments
  79. 7.14 LEO Pharma
  80. 7.14.1 LEO Pharma Company Information
  81. 7.14.2 LEO Pharma Business Overview
  82. 7.14.3 LEO Pharma Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 LEO Pharma Semi-Solid Dosage Form Product Portfolio
  84. 7.14.5 LEO Pharma Recent Developments
  85. 7.15 Mylan N.V.
  86. 7.15.1 Mylan N.V. Company Information
  87. 7.15.2 Mylan N.V. Business Overview
  88. 7.15.3 Mylan N.V. Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Mylan N.V. Semi-Solid Dosage Form Product Portfolio
  90. 7.15.5 Mylan N.V. Recent Developments
  91. 7.16 Novartis AG
  92. 7.16.1 Novartis AG Company Information
  93. 7.16.2 Novartis AG Business Overview
  94. 7.16.3 Novartis AG Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Novartis AG Semi-Solid Dosage Form Product Portfolio
  96. 7.16.5 Novartis AG Recent Developments
  97. 7.17 Perrigo Pharma
  98. 7.17.1 Perrigo Pharma Company Information
  99. 7.17.2 Perrigo Pharma Business Overview
  100. 7.17.3 Perrigo Pharma Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Perrigo Pharma Semi-Solid Dosage Form Product Portfolio
  102. 7.17.5 Perrigo Pharma Recent Developments
  103. 7.18 Taro Pharmaceutical Industries Ltd.
  104. 7.18.1 Taro Pharmaceutical Industries Ltd. Company Information
  105. 7.18.2 Taro Pharmaceutical Industries Ltd. Business Overview
  106. 7.18.3 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio
  108. 7.18.5 Taro Pharmaceutical Industries Ltd. Recent Developments
  109. 7.19 Teligent Pharma
  110. 7.19.1 Teligent Pharma Company Information
  111. 7.19.2 Teligent Pharma Business Overview
  112. 7.19.3 Teligent Pharma Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Teligent Pharma Semi-Solid Dosage Form Product Portfolio
  114. 7.19.5 Teligent Pharma Recent Developments
  115. 7.20 Bayer AG
  116. 7.20.1 Bayer AG Company Information
  117. 7.20.2 Bayer AG Business Overview
  118. 7.20.3 Bayer AG Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Bayer AG Semi-Solid Dosage Form Product Portfolio
  120. 7.20.5 Bayer AG Recent Developments
  121. 7.21 GlaxoSmithKline plc
  122. 7.21.1 GlaxoSmithKline plc Company Information
  123. 7.21.2 GlaxoSmithKline plc Business Overview
  124. 7.21.3 GlaxoSmithKline plc Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio
  126. 7.21.5 GlaxoSmithKline plc Recent Developments
  127. 7.22 Merck & Co
  128. 7.22.1 Merck & Co Company Information
  129. 7.22.2 Merck & Co Business Overview
  130. 7.22.3 Merck & Co Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Merck & Co Semi-Solid Dosage Form Product Portfolio
  132. 7.22.5 Merck & Co Recent Developments
  133. 7.23 Johnson & Johnson
  134. 7.23.1 Johnson & Johnson Company Information
  135. 7.23.2 Johnson & Johnson Business Overview
  136. 7.23.3 Johnson & Johnson Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Johnson & Johnson Semi-Solid Dosage Form Product Portfolio
  138. 7.23.5 Johnson & Johnson Recent Developments
  139. 7.24 Nestlé SA
  140. 7.24.1 Nestlé SA Company Information
  141. 7.24.2 Nestlé SA Business Overview
  142. 7.24.3 Nestlé SA Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Nestlé SA Semi-Solid Dosage Form Product Portfolio
  144. 7.24.5 Nestlé SA Recent Developments
  145. 7.25 Sun Pharmaceuticals
  146. 7.25.1 Sun Pharmaceuticals Company Information
  147. 7.25.2 Sun Pharmaceuticals Business Overview
  148. 7.25.3 Sun Pharmaceuticals Semi-Solid Dosage Form Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  150. 7.25.5 Sun Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Semi-Solid Dosage Form Market Size by Type
  2. 8.1.1 North America Semi-Solid Dosage Form Revenue by Type (2021-2032)
  3. 8.1.2 North America Semi-Solid Dosage Form Sales by Type (2021-2032)
  4. 8.1.3 North America Semi-Solid Dosage Form Price by Type (2021-2032)
  5. 8.2 North America Semi-Solid Dosage Form Market Size by Application
  6. 8.2.1 North America Semi-Solid Dosage Form Revenue by Application (2021-2032)
  7. 8.2.2 North America Semi-Solid Dosage Form Sales by Application (2021-2032)
  8. 8.2.3 North America Semi-Solid Dosage Form Price by Application (2021-2032)
  9. 8.3 North America Semi-Solid Dosage Form Market Size by Country
  10. 8.3.1 North America Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Semi-Solid Dosage Form Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Semi-Solid Dosage Form Market Size by Type
  2. 9.1.1 Europe Semi-Solid Dosage Form Revenue by Type (2021-2032)
  3. 9.1.2 Europe Semi-Solid Dosage Form Sales by Type (2021-2032)
  4. 9.1.3 Europe Semi-Solid Dosage Form Price by Type (2021-2032)
  5. 9.2 Europe Semi-Solid Dosage Form Market Size by Application
  6. 9.2.1 Europe Semi-Solid Dosage Form Revenue by Application (2021-2032)
  7. 9.2.2 Europe Semi-Solid Dosage Form Sales by Application (2021-2032)
  8. 9.2.3 Europe Semi-Solid Dosage Form Price by Application (2021-2032)
  9. 9.3 Europe Semi-Solid Dosage Form Market Size by Country
  10. 9.3.1 Europe Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Semi-Solid Dosage Form Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Semi-Solid Dosage Form Market Size by Type
  2. 10.1.1 China Semi-Solid Dosage Form Revenue by Type (2021-2032)
  3. 10.1.2 China Semi-Solid Dosage Form Sales by Type (2021-2032)
  4. 10.1.3 China Semi-Solid Dosage Form Price by Type (2021-2032)
  5. 10.2 China Semi-Solid Dosage Form Market Size by Application
  6. 10.2.1 China Semi-Solid Dosage Form Revenue by Application (2021-2032)
  7. 10.2.2 China Semi-Solid Dosage Form Sales by Application (2021-2032)
  8. 10.2.3 China Semi-Solid Dosage Form Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Semi-Solid Dosage Form Market Size by Type
  2. 11.1.1 Asia Semi-Solid Dosage Form Revenue by Type (2021-2032)
  3. 11.1.2 Asia Semi-Solid Dosage Form Sales by Type (2021-2032)
  4. 11.1.3 Asia Semi-Solid Dosage Form Price by Type (2021-2032)
  5. 11.2 Asia Semi-Solid Dosage Form Market Size by Application
  6. 11.2.1 Asia Semi-Solid Dosage Form Revenue by Application (2021-2032)
  7. 11.2.2 Asia Semi-Solid Dosage Form Sales by Application (2021-2032)
  8. 11.2.3 Asia Semi-Solid Dosage Form Price by Application (2021-2032)
  9. 11.3 Asia Semi-Solid Dosage Form Market Size by Country
  10. 11.3.1 Asia Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Semi-Solid Dosage Form Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Semi-Solid Dosage Form Market Size by Type
  2. 12.1.1 SAMEA Semi-Solid Dosage Form Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Semi-Solid Dosage Form Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Semi-Solid Dosage Form Price by Type (2021-2032)
  5. 12.2 SAMEA Semi-Solid Dosage Form Market Size by Application
  6. 12.2.1 SAMEA Semi-Solid Dosage Form Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Semi-Solid Dosage Form Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Semi-Solid Dosage Form Price by Application (2021-2032)
  9. 12.3 SAMEA Semi-Solid Dosage Form Market Size by Country
  10. 12.3.1 SAMEA Semi-Solid Dosage Form Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Semi-Solid Dosage Form Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Semi-Solid Dosage Form Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Semi-Solid Dosage Form Value Chain Analysis
  2. 13.1.1 Semi-Solid Dosage Form Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Semi-Solid Dosage Form Production Mode & Process
  6. 13.2 Semi-Solid Dosage Form Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Semi-Solid Dosage Form Distributors
  9. 13.2.3 Semi-Solid Dosage Form Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst